AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19540054
Drug: Treatment plans
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment plans meeting dose-volume constraints (V30<=80%, V40<=65%, V50<=55%, V60<=40%, V65<=30%, V70<=15%, V75<=3%)
Trial: 10426891
Drug: Doxepin/TAC cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin/TAC cream (0.025% triamcinolone acetonide)
Trial: 10426891
Drug: Doxepin cream
RxNorm normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin cream (5% doxepin hydrochloride)
Trial: 7547092
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium 120 mg day‐1
Trial: 2158440
Drug: ZK 95962
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 95962 (20 micrograms/kg body weight, 2 injections, 10 min apart)
Trial: 24211163
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg orally once daily) plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Trial: 24211163
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Trial: 24211163
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg orally once daily) plus docetaxel
Trial: 21430254
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of L-essential amino acids (EAA)
Trial: 21430254
Drug: rapamycin (mTORC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapamycin (mTORC1 inhibitor) prior to EAA ingestion
Trial: 31838589
Drug: PATCH (motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATCH (motivational enhancement intervention)
Trial: 24783925
Drug: Jianpi suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi suppository
Trial: 23240940
Drug: Intranasal reduced
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal reduced glutathione (in)GSH
Trial: 17092412
Drug: Ulinastatin plus
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week
Trial: 12872390
Drug: Combined medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medicine (CAL and western medicine)
Trial: 12872390
Drug: CAL (composite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL (composite agastache lotion)
Trial: 1762283
Drug: Verapamil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (20 patients), daily dose 60‐120 mg, mean 80 mg
Trial: 1762283
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 patients), daily dose 120‐180 mg, mean 140 mg
Trial: 7050868
Drug: Gentamicin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (2.5 mg/kg q6h)
Trial: 7050868
Drug: Colistin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (1 mg/kg q6h)
Trial: 4026058
Drug: HFCWO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCWO at 5 Hz with 20 ml tidal volume (Series B)
Trial: 4026058
Drug: HFCWO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCWO at 5 Hz with 40 ml tidal volume (Series C)
Trial: 31197507
Drug: Juçara freeze-dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juçara freeze-dried pulp (5 g)
Trial: 31197507
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g)
Trial: 10609975
Drug: MTT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTT with contingency contracts using monetary reinforcers targeting abstinence from illicit drug and alcohol use
Trial: 16272751
Drug: Landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Landiolol hydrochloride (low dose: 0.03 mg/kg/min for 1 min loading, then 0.01 mg/kg/min for 10 min continuous)
Trial: 16272751
Drug: Landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Landiolol hydrochloride (medium dose: 0.06 mg/kg/min for 1 min loading, then 0.02 mg/kg/min for 10 min continuous)
Trial: 11579113
Drug: FEC (fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (fluorouracil, epirubicin, and cyclophosphamide) chemotherapy, six cycles
Trial: 1297554
Drug: Cervical collar
RxNorm normalized name: Cervical Collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical collar therapy
Trial: 9089428
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg once daily for a maximum of 10 weeks)
Trial: 9089428
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg once daily for a maximum of 10 weeks)
Trial: 9089428
Drug: Metolazone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone (1 mg once daily for a maximum of 10 weeks)
Trial: 8404433
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg three times a day)
Trial: 3544188
Drug: Carbenoxolone/antacid/alginate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone/antacid/alginate preparation (Pyrogastrone)
Trial: 3544188
Drug: Antacid/alginate alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid/alginate alone (Control)
Trial: 28853967
Drug: Monopolar RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monopolar RF device treatment (4 once-a-week sessions)
Trial: 27039080
Drug: Rosuvastatin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin at 20 mg/day
Trial: 27039080
Drug: Ezetimibe at
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe at 10 mg/day
Trial: 27039080
Drug: Colestimide at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide at 3.62 g/day
Trial: 10233878
Drug: combined decontamination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined decontamination medication
Trial: 8912751
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation at 25 ppm
Trial: 29698250
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (5 mg/kg)
Trial: 27154174
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg co-administered with vismodegib 150 mg QD for 7 days
Trial: 27154174
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg co-administered with vismodegib 150 mg QD for 7 days
Trial: 27154174
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg co-administered with vismodegib 150 mg QD for 7 days
Trial: 27154174
Drug: Control arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm: Vismodegib 150 mg QD for 7 days
Trial: 23402387
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not on treatment)
Trial: 15319760
Drug: Non-Spinal Manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Spinal Manipulation Treatment (N-SMT)
Trial: 9234829
Drug: Cicletanine 100
RxNorm normalized name: cicletanine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 100 mg orally daily for 1 week
Trial: 8270925
Drug: Vigabatrin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (1 g twice daily for six weeks, followed by 1.5 g twice daily for a further six weeks)
Trial: 25048345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ECG variables
Trial: 22203755
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg twice per day
Trial: 22203755
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg twice per day
Trial: 22203755
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² intravenously every 28 days
Trial: 20729336
Drug: Daily assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assessments of positive affect (PA) and relatedness needs satisfaction (RNS) in Study 4
Trial: 18611273
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus a platinum compound
Trial: 8863239
Drug: Conservative, delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative, delayed surgery after intensive chemotherapy with or without radiotherapy
Trial: 8863239
Drug: Additional chemotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional chemotherapy and late exenteration, prostatectomy, or biopsy for patients with relapse or residual disease
Trial: 8863239
Drug: Gross primary
RxNorm normalized name: Ostericum grosseserratum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gross primary excision, local radiotherapy, and vincristine and actinomycin therapy for group IIA tumors
Trial: 1651360
Drug: CMV-specific intravenous
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV-specific intravenous immunoglobulin (IVIG) 200 mg/kg on days 8 and 6 before transplant, the day after transplant, weekly for the first month, and then every 2 weeks to complete 10 doses
Trial: 30730425
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration therapy
Trial: 24655598
Drug: No-drug control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug control
Trial: 24507823
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml wine
Trial: 24507823
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml wine
Trial: 24507823
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml wine
Trial: 24507823
Drug: Cut-off value
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cut-off value of 8.84 μg/mg creatinine
Trial: 22853848
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/Amlodipine 5 mg (I150/A5)
Trial: 22853848
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/Amlodipine 10 mg (I150/A10)
Trial: 17158003
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) users
Trial: 12510212
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg transdermal estradiol
Trial: 12510212
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg transdermal estradiol
Trial: 350397
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with bacillus Calmette‐Guérin
Trial: 350397
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Corynebacterium parvum (C. parvum)
Trial: 350397
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (MOCA)
Trial: 31443893
Drug: Mindfulness practice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness practice time without minimum treatment dose requirement
Trial: 25817373
Drug: Low-dose adenovirus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adenovirus type-5 vector-based Ebola vaccine
Trial: 25817373
Drug: High-dose adenovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adenovirus type-5 vector-based Ebola vaccine
Trial: 27852684
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day resveratrol (resVida)
Trial: 19037040
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 800 mcg
Trial: 23102797
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 800 mcg
Trial: 16925756
Drug: Adjuvant luteinizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant luteinizing hormone-releasing hormone (LHRH) agonist in Study 1
Trial: 16925756
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist monotherapy or combined androgen blockade in Study 2
Trial: 14517191
Drug: Mibefradil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (100 mg oral dose)
Trial: 1410164
Drug: Nicotine (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.4, 0.6, and 0.8 mg subcutaneously)
Trial: 23195963
Drug: Oral enteric
RxNorm normalized name: Ascriptin Enteric Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteric insulin 50 U
Trial: 23195963
Drug: Oral enteric
RxNorm normalized name: Ascriptin Enteric Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteric insulin 100 U
Trial: 23195963
Drug: Oral enteric
RxNorm normalized name: Ascriptin Enteric Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteric insulin 200 U
Trial: 23195963
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 6 U
Trial: 15385809
Drug: Basiliximab (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (two 20-mg doses on days 0 and 4) + Tacrolimus (0.15 mg/kg/day; target trough levels 10-15 ng/mL)
Trial: 9714353
Drug: Larsen's (L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larsen's (L) radiological scoring method
Trial: 8790563
Drug: Pre-S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-S vaccine (12 micrograms, 24 micrograms, 48 micrograms)
Trial: 8790563
Drug: Pre-S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-S vaccine (48 micrograms)
Trial: 8790563
Drug: Pre-S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-S vaccine (any dose)
Trial: 24267730
Drug: Everolimus (EVE)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVE) 10 mg/d plus Exemestane (EXE) 25 mg/d
Trial: 21603651
Drug: ADVAX 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX 0.2 mg via electroporation
Trial: 21603651
Drug: ADVAX 1
RxNorm normalized name: Tdvax
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX 1 mg via electroporation
Trial: 21603651
Drug: ADVAX 4
RxNorm normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX 4 mg via electroporation
Trial: 21603651
Drug: ADVAX 4
RxNorm normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX 4 mg via standard intramuscular injection
Trial: 21603651
Drug: ADVAX 4
RxNorm normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX 4 mg via electroporation (third vaccination at week 36)
Trial: 15064942
Drug: oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral iron
Trial: 11996476
Drug: Vinorelbine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 20 mg/m2 (or 15 mg/m2 if prior pelvic radiotherapy) combined with estramustine phosphate (EMP) at 280 mg orally tds for 3 days, then every other week after 8 weeks
Trial: 8085286
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody assays (MAAs)
Trial: 8085286
Drug: MAA values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAA values of 10, 15, and 20 micrograms/ml
Trial: 23057495
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oxaliplatin (oxaliplatin 50 mg/m² on days 1, 8, 22, and 29; S-1 80 mg/m² per day on days 1-14 and 22-35)
Trial: 15160576
Drug: Non-adherent gauze
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherent gauze plus compression therapy
Trial: 11176329
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) with smectite
Trial: 9847464
Drug: Electron beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electron beam treatment (9/12 MeV and 12 MeV) to chest wall and drainage area, 50 Gy over 5 weeks at 2 Gy per fraction.
Trial: 9847464
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) for pre-menopausal patients with axillary node involvement.
Trial: 9847464
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen 10 mg bid for post-menopausal patients.
Trial: 9847464
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (Electron beam)
Trial: 2643331
Drug: Acetazolamide tablets
RxNorm normalized name: Acetazolamide Tablets
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide tablets (500 mg)
Trial: 2643331
Drug: Methazolamide tablets
RxNorm normalized name: Methazolamide Tablets
DrugBank: Methazolamide (DB00703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methazolamide tablets
Trial: 2643331
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with carbonic anhydrase inhibitors
Trial: 788494
Drug: Zinc supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplemented formula (4 mg/liter of zinc)
Trial: 27883201
Drug: VIA-2291 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIA-2291 (25 mg, 50 mg, 100 mg)
Trial: 20577750
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing genistein (97 μg daily for 15 days/month for 3 months)
Trial: 20577750
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing hyaluronic acid (5 mg daily for 15 days/month for 3 months)
Trial: 19344224
Drug: Intravenous EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous EPO (30,000 U) every 48 hours for a total of 90,000 U
Trial: 16765169
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally 1 hour before UDS
Trial: 16281654
Drug: alendronate/calcium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alendronate/calcium (10 mg/600 mg day)
Trial: 8109217
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion (serum ethanol concentration of 0.98 +/- 0.22 g/l)
Trial: 3311904
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 g dose tetracycline
Trial: 3311904
Drug: Single 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 g dose tetracycline
Trial: 3311904
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose tetracycline (500 mg every six hours, four times)
Trial: 26732944
Drug: CINV control
RxNorm normalized name: Cinvanti
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CINV control (total control: no vomiting, no nausea, and no rescue medication)